Grifols plans to release Phase III results of its long-term albumin treatment designed to increase survival time in patients with decompensated cirrhosis and ascites in 2024, says chief scientific ...

Nearly one million people in the U.S. and more than six million people worldwide have Parkinson's disease (PD), a debilitating neurological condition characterized by progressive motor and non-motor ...

At the same time, Grifols has formed a strategic alliance with Haier in the market for plasma products, particularly albumin, and diagnostics. It has been involved in a series of acquisitions in ...

Learn more about whether Alkermes plc or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which ...

Learn more about whether Exact Sciences Corporation or Grifols, S.A. is a better investment based on AAII's A+ Investor ...

Based on the available evidence, the addition of albumin to PN solutions cannot be recommended. The potential for complications due to infection and physical and chemical incompatibility and ...

Grifols and SRAAS extend their exclusive albumin distribution agreement over the next 10 years, and SRAAS has the option to prolong it through 2044Grifols will use al With Biotest-developed ...

Industry Major Player: Grifols S.A. Grifols S.A ... such as Recombinant Human Serum Albumin rHSA Albumin-based therapy innovations, like the development of recombinant human serum albumin rHSA ...

For example, Grifols has announced plans to increase ... especially in immune globulins and albumin derivatives. The market for rare and specialized plasma-derived therapies is expected to grow ...

Factor IX Concentrate: This product is vital for treating hemophilia B, contributing to about 15% of market share. Albumin: Commonly used in critical care settings and for liver diseases, albumin ...